Lifespan and healthspan extension by resveratrol

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2015, Pages 1209-1218

  Bhullar, Khushwant S ^a   Hubbard, Basil P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clinical trials; Disease prevention; Healthspan extension; Lifespan extension; Resveratrol; Sirtuin activating compounds

Indexed keywords

RESVERATROL; STILBENES;

ANIMALS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HUMANS; LONGEVITY;

ANIMALS; DRUG DESIGN; HUMANS; LONGEVITY; STILBENES;

EID: 84939962219     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.01.012     Document Type: Review

References (159)

1. Kenyon C. The first long-lived mutants: discovery of theinsulin/IGF-1 pathway for ageing. Phil. Trans. R. Soc. B 2011, 366:9-16. 10.1098/rstb.2010.0276.
2. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
3. Hansen M., Taubert S., Crawford D., Libina N., Lee S.J., Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 2007, 6:95-110.
4. Kaeberlein M., McVey M., Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999, 13:2570-2580.
5. Anderson R.M., Bitterman K.J., Wood J.G., Medvedik O., Sinclair D.A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 2003, 423:181-185.
6. Lee G.D., Wilson M.A., Zhu M., Wolkow C.A., de Cabo R., Ingram D.K., Zou S. Dietary deprivation extends lifespan in Caenorhabditis elegans. Aging Cell 2006, 5:515-524.
7. Partridge L., Piper M.D., Mair W. Dietary restriction in Drosophila. Mech. Ageing Dev. 2005, 126:938-950.
8. Weindruch R., Walford R.L., Fligiel S., Guthrie D. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J. Nutr. 1986, 116:641-654.
9. Mattison J.A., Roth G.S., Beasley T.M., Tilmont E.M., Handy A.M., Herbert R.L., Longo D.L., Allison D.B., Young J.E., Bryant M., Barnard D., Ward W.F., Qi W., Ingram D.K., de Cabo R. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012, 489:318-321.
10. Colman R.J., Beasley T.M., Kemnitz J.W., Johnson S.C., Weindruch R., Anderson R.M. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 2014, 5:3557.
11. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
12. Bodkin N.L., Alexander T.M., Ortmeyer H.K., Johnson E., Hansen B.C. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J. Gerontol. A: Biol. Med. Sci. 2003, 58:B212-B219.
13. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
14. Martin-Montalvo A., Mercken E.M., Mitchell S.J., Palacios H.H., Mote P.L., Scheibye-Knudsen M., Gomes A.P., Ward T.M., Minor R.K., Blouin M.J., Schwab M., Pollak M., Zhang Y., Yu Y., Becker K.G., Bohr V.A., Ingram D.K., Sinclair D.A., Wolf N.S., Spindler S.R., Bernier M., de Cabo R. Metformin improves healthspan and lifespan in mice. Nat. Commun. 2013, 4:2192.
15. Morselli E., Galluzzi L., Kepp O., Criollo A., Maiuri M.C., Tavernarakis N., Madeo F., Kroemer G. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging 2009, 1:961-970.
16. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
17. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
18. Hubbard B.P., Sinclair D.A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 2014, 35:146-154.
19. Takaoka M. Resveratrol, a new phenolic compound from Veratrum grandiflorum. Nippon Kagaku Kaishi 1939, 60:1090-1100.
20. Mattivi F., Reniero F., Korhammer S. Isolation, characterization, and evolution in red wine vinification of resveratrol monomers. J. Agric. Food Chem. 1995, 43:1820-1823.
21. Cao H., Pan X., Li C., Zhou C., Deng F., Li T. Density functional theory calculations for resveratrol. Bioorg. Med. Chem. Lett. 2003, 13:1869-1871.
22. Queiroz A.N., Gomes B.A., Moraes W.M., Borges R.S. A theoretical antioxidant pharmacophore for resveratrol. Eur. J. Med. Chem. 2009, 44:1644-1649.
23. Frankel E., Waterhouse A., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 1993, 341:1103-1104.
24. Blond J., Denis M., Bezard J. Antioxidant action of resveratrol in lipid peroxidation. Sci. Aliments 1995, 15:347-358. (France).
25. Rotondo S., Rajtar G., Manarini S., Celardo A., Rotilio D., De Gaetano G., Evangelista V., Cerletti C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br. J. Pharmacol. 1998, 123:1691-1699.
26. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
27. Virgili M., Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 2000, 281:123-126.
28. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci. 2008, 99:1501-1506.
29. Kundu J.K., Shin Y.K., Surh Y.-J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-κB and AP-1 as prime targets. Biochem. Pharmacol. 2006, 72:1506-1515.
30. Wilson T., Knight T.J., Beitz D.C., Lewis D.S., Engen R.L. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996, 59:L15-PL21.
31. Breinholt V.M., Mølck A.-M., Svendsen G.W., Daneshvar B., Vinggaard A.M., Poulsen M., Dragsted L.O. Effects of dietary antioxidants and 2-amino-3-methylimidazo [4, 5-f]-quinoline (IQ) on preneoplastic lesions and on oxidative damage, hormonal status, and detoxification capacity in the rat. Food Chem. Toxicol. 2003, 41:1315-1323.
32. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
33. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273:793-798.
34. Denu J.M. The Sir2 family of protein deacetylases. Curr. Opin. Chem. Biol. 2005, 9:431-440.
35. Shore D., Squire M., Nasmyth K.A. Characterization of two genes required for the position-effect control of yeast mating-type genes. EMBO J. 1984, 3:2817-2823.
36. Sinclair D.A., Guarente L. Extrachromosomal rDNA circles-a cause of aging in yeast. Cell 1997, 91:1033-1042.
37. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
38. Rogina B., Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15998-16003.
39. Kanfi Y., Naiman S., Amir G., Peshti V., Zinman G., Nahum L., Bar-Joseph Z., Cohen H.Y. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221.
40. Satoh A., Brace C.S., Rensing N., Cliften P., Wozniak D.F., Herzog E.D., Yamada K.A., Imai S. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013, 18:416-430.
41. Herranz D., Muñoz-Martin M., Cañamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., Serrano M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
42. Guarente L., Picard F. Calorie restriction-the SIR2 connection. Cell 2005, 120:473-482.
43. Kaeberlein M., Kirkland K.T., Fields S., Kennedy B.K. Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol. 2004, 2:e296.
44. Lamming D.W., Latorre-Esteves M., Medvedik O., Wong S.N., Tsang F.A., Wang C., Lin S.J., Sinclair D.A. HST2 mediates SIR2-independent life-span extension by calorie restriction. Science 2005, 309:1861-1864.
45. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
46. Palacios O.M., Carmona J.J., Michan S., Chen K.Y., Manabe Y., Ward Iii J.L., Goodyear L.J., Tong Q. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1α in skeletal muscle. Aging (Albany NY) 2009, 1:771.
47. Boily G., Seifert E.L., Bevilacqua L., He X.H., Sabourin G., Estey C., Moffat C., Crawford S., Saliba S., Jardine K. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS One 2008, 3:e1759.
48. Qiu X., Brown K., Hirschey M.D., Verdin E., Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010, 12:662-667.
49. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., Agarwal B., Ye L., Ramadori G., Teodoro J.S., Hubbard B.P., Varela A.T., Davis J.G., Varamini B., Hafner A., Moaddel R., Rolo A.P., Coppari R., Palmeira C.M., de Cabo R., Baur J.A., Sinclair D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
50. Morris B.J. Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. 2013, 56:133-171.
51. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
52. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell 2010, 142:320-332.
53. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26:3169-3179.
54. Liu T., Liu P.Y., Marshall G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009, 69:1702-1705.
55. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
56. Borradaile N.M., Pickering J.G. NAD+, sirtuins, and cardiovascular disease. Curr. Pharm. Des. 2009, 15:110-117.
57. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
58. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S.D., Napper A., Curtis R., DiStefano P.S., Fields S., Bedalov A., Kennedy B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 2005, 280:17038-17045.
59. Chung J.H. Using PDE inhibitors to harness the benefits of calorie restriction: lessons from resveratrol. Aging (Albany NY) 2012, 4:144-145.
60. Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., Yen S., Lamming D.W. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
61. Lakshminarasimhan M., Rauh D., Schutkowski M., Steegborn C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY) 2013, 5:151-154.
62. Bass T.M., Weinkove D., Houthoofd K., Gems D., Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 2007, 128:546-552.
63. Burnett C., Valentini S., Cabreiro F., Goss M., Somogyvári M., Piper M.D., Hoddinott M., Sutphin G.L., Leko V., McElwee J.J. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011, 477:482-485.
64. Viswanathan M., Guarente L. Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes. Nature 2011, 477:E1-E2.
65. Wang C., Wheeler C.T., Alberico T., Sun X., Seeberger J., Laslo M., Spangler E., Kern B., de Cabo R., Zou S. The effect of resveratrol on lifespan depends on both gender and dietary nutrient composition in Drosophila melanogaster. Age 2013, 35:69-81.
66. Rascón B., Hubbard B.P., Sinclair D.A., Amdam G.V. The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging (Albany NY) 2012, 4:499.
67. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16:296-300.
68. Yu X., Li G. Effects of resveratrol on longevity, cognitive ability and aging-related histological markers in the annual fish Nothobranchius guentheri. Exp. Gerontol. 2012, 47:940-949.
69. Genade T., Lang D. Resveratrol extends lifespan and preserves glia but not neurons of the Nothobranchius guentheri optic tectum. Exp. Gerontol. 2013, 48:202-212.
70. Kim E., Ansell C.M., Dudycha J.L. Resveratrol and food effects on lifespan and reproduction in the model crustacean Daphnia. J. Exp. Zool. A Ecol. Genet. Physiol. 2014, 321:48-56.
71. Resveratrol supplementation Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol. 2003, 186(1):28-37.
72. Chen W., Rezaizadehnajafi L., Wink M. Influence of resveratrol on oxidative stress resistance and life span in Caenorhabditis elegans. J. Pharm. Pharmacol. 2013, 65:682-688.
73. Ye K., Ji C.-B., Lu X.-W., Ni Y.-H., Gao C.-L., Chen X.-H., Zhao Y.-P., Gu G.-X., Guo X.-R. Resveratrol attenuates radiation damage in Caenorhabditis elegans by preventing oxidative stress. J. Radiat. Res. 2010, 51:473-479.
74. Chang C.L., Follett P. Resveratrol modifies tephritid fruit fly response to radiation but not nutritional stress. Int. J. Radiat. Biol. 2012, 88:320-326.
75. Yin H., Si J., Xu H., Dong J., Zheng D., Lu X., Li X. Resveratrol-loaded nanoparticles reduce oxidative stress induced by radiation or amyloid-beta in transgenic Caenorhabditis elegans. J. Biomed. Nanotechnol. 2014, 10:1536-1544.
76. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
77. Miller R.A., Harrison D.E., Astle C., Baur J.A., Boyd A.R., de Cabo R., Fernandez E., Flurkey K., Javors M.A., Nelson J.F. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A: Biol. Med. Sci. 2010, glq178.
78. Strong R., Miller R.A., Astle C.M., Baur J.A., de Cabo R., Fernandez E., Guo W., Javors M., Kirkland J.L., Nelson J.F. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J. Gerontol. A: Biol. Med. Sci. 2013, 68:6-16.
79. da Luz P.L., Tanaka L., Brum P.C., Dourado P.M.M., Favarato D., Krieger J.E., Laurindo F.R.M. Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats. Atherosclerosis 2012, 224:136-142.
80. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
81. Oberdoerffer P., Michan S., McVay M., Mostoslavsky R., Vann J., Park S.K., Hartlerode A., Stegmuller J., Hafner A., Loerch P., Wright S.M., Mills K.D., Bonni A., Yankner B.A., Scully R., Prolla T.A., Alt F.W., Sinclair D.A. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008, 135:907-918.
82. Oliveira Andrade J.M., Paraíso A.F., Macedo de Oliveira M.V., de Barros Lima Martins A.M.E., Rodrigues Neto J.F., Sena Guimarães A.L., Batista de Paula A.M., Qureshi M., Sousa Santos S.H. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 2014, 30(7-8):915-919. 10.1016/j.nut.2013.11.016.
83. Wang B., Sun J., Ma Y., Wu G., Tian Y., Shi Y., Le G. Resveratrol preserves mitochondrial function, stimulates mitochondrial biogenesis, and attenuates oxidative stress in regulatory t cells of mice fed a high-fat diet. J. Food Sci. 2014, 79(9):H1823-H1831. 10.1111/1750-3841.12555.
84. Jimenez-Gomez Y., Mattison J.A., Pearson K.J., Martin-Montalvo A., Palacios H.H., Sossong A.M., Ward T.M., Younts C.M., Lewis K., Allard J.S., Longo D.L., Belman J.P., Malagon M.M., Navas P., Sanghvi M., Moaddel R., Tilmont E.M., Herbert R.L., Morrell C.H., Egan J.M., Baur J.A., Ferrucci L., Bogan J.S., Bernier M., de Cabo R. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab. 2013, 18:533-545.
85. Mattison J.A., Wang M., Bernier M., Zhang J., Park S.S., Maudsley S., An S.S., Santhanam L., Martin B., Faulkner S., Morrell C., Baur J.A., Peshkin L., Sosnowska D., Csiszar A., Herbert R.L., Tilmont E.M., Ungvari Z., Pearson K.J., Lakatta E.G., de Cabo R. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab. 2014, 20:183-190.
86. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14:612-622.
87. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S.B., Jorgensen J.O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
88. Ornstrup M.J., Harslof T., Kjaer T.N., Langdahl B.L., Pedersen S.B. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J. Clin. Endocrinol. Metab. 2014, jc20142799.
89. Brasnyó P., Molnár G.A., Mohás M., Markó L., Laczy B., Cseh J., Mikolás E., Szijártó I.A., Mérei A., Halmai R. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106:383-389.
90. Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 2014, 34(10):837-843. 10.1016/j.nutres.2014.09.005.
91. Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sullivan T.M., Lee P., Franklin M., Klein K., Taylor P.J., Ferguson M., Coombes J.S., Thomas G.P., Cowin G.J., Kirkpatrick C.M., Prins J.B., Hickman I.J. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014, 12(12):2092-2103.e1-6. 10.1016/j.cgh.2014.02.024.
92. Knop F.K., Konings E., Timmers S., Schrauwen P., Holst J.J., Blaak E.E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 2013, 30:1214-1218.
93. Song L., Chen L., Zhang X., Li J., Le W. Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1 G93A mouse model of amyotrophic lateral sclerosis. BioMed Res. Int. 2014, 2014.
94. Mancuso R., del Valle J., Modol L., Martinez A., Granado-Serrano A.B., Ramirez-Núñez O., Pallás M., Portero-Otin M., Osta R., Navarro X. Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice. Neurotherapeutics 2014, 11:419-432.
95. Porquet D., Casadesús G., Bayod S., Vicente A., Canudas A.M., Vilaplana J., Pelegrí C., Sanfeliu C., Camins A., Pallàs M. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age 2013, 35:1851-1865.
96. Gerhardt E., Gräber S., Szego É.M., Moisoi N., Martins L.M., Outeiro T.F., Kermer P. Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS One 2011, 6:e28855.
97. Rimbaud S., Ruiz M., Piquereau J., Mateo P., Fortin D., Veksler V., Garnier A., Ventura-Clapier R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 2011, 6:e26391.
98. Klink J.C., Tewari A.K., Masko E.M., Antonelli J., Febbo P.G., Cohen P., Dewhirst M.W., Pizzo S.V., Freedland S.J. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 2013, 73:754-762.
99. Avila P.R., Marques S.O., Luciano T.F., Vitto M.F., Engelmann J., Souza D.R., Pereira S.V., Pinho R.A., Lira F.S., De Souza C.T. Resveratrol and fish oil reduce catecholamine-induced mortality in obese rats: role of oxidative stress in the myocardium and aorta. Br. J. Nutr. 2013, 110:1580-1590.
100. Sebai H., Sani M., Ghanem-Boughanmi N., Aouani E. Prevention of lipopolysaccharide-induced mouse lethality by resveratrol. Food Chem. Toxicol. 2010, 48:1543-1549.
101. Holthoff J.H., Wang Z., Seely K.A., Gokden N., Mayeux P.R. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 2011, 81:370-378.
102. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., Wang Y., Raederstorff D., Morrow J.D., Leeuwenburgh C. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3:e2264.
103. Marchal J., Blanc S., Epelbaum J., Aujard F., Pifferi F. Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One 2012, 7:e34289.
104. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32:537-541.
105. Tome-Carneiro J., Larrosa M., Yanez-Gascon M.J., Davalos A., Gil-Zamorano J., Gonzalvez M., Garcia-Almagro F.J., Ruiz Ros J.A., Tomas-Barberan F.A., Espin J.C., Garcia-Conesa M.T. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72:69-82.
106. Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., Brown K., Steward W., Gescher A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4:1419-1425.
107. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280:37377-37382.
108. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54:111-118.
109. Smoliga J.M., Baur J.A., Hausenblas H.A. Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55:1129-1141.
110. Ku C.R., Lee H.J., Kim S.K., Lee E.Y., Lee M.K., Lee E.J. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic beta-cell and the cleavage of poly(ADP-ribose) polymerase. Endocr. J. 2012, 59:103-109.
111. Fiori J.L., Shin Y.K., Kim W., Krzysik-Walker S.M., Gonzalez-Mariscal I., Carlson O.D., Sanghvi M., Moaddel R., Farhang K., Gadkaree S.K., Doyle M.E., Pearson K.J., Mattison J.A., de Cabo R., Egan J.M. Resveratrol prevents beta-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 2013, 62:3500-3513.
112. Park D.W., Kim J.S., Chin B.R., Baek S.H. Resveratrol inhibits inflammation induced by heat-killed Listeria monocytogenes. J. Med. Food 2012, 15:788-794.
113. Elmali N., Baysal O., Harma A., Esenkaya I., Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007, 30:1-6.
114. Wu J.M., Hsieh T.C. Resveratrol: a cardioprotective substance. Ann. N. Y. Acad. Sci. 2011, 1215:16-21.
115. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi Fanelli F., Patterson B.W., Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012, 16:658-664.
116. Block G., Jensen C.D., Norkus E.P., Dalvi T.B., Wong L.G., McManus J.F., Hudes M.L. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 2007, 6:30.
117. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
118. Chung J.H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte 2012, 1:256-258.
119. Yu C., Shin Y.G., Kosmeder J.W., Pezzuto J.M., van Breemen R.B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun. Mass Spectrom. 2003, 17:307-313.
120. Piver B., Berthou F., Dreano Y., Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 2001, 125:83-91.
121. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58:5707-5712.
122. Cai J.B., Zhang Z.H., Xu D.J., Qian Z.Y., Wang Z.R., Huang Y.Z., Zou J.G., Cao K.J. Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 2008, 35:1419-1425.
123. Murias M., Handler N., Erker T., Pleban K., Ecker G., Saiko P., Szekeres T., Jager W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 2004, 12:5571-5578.
124. Haworth R.S., Avkiran M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 2001, 62:1647-1651.
125. Armour S.M., Baur J.A., Hsieh S.N., Land-Bracha A., Thomas S.M., Sinclair D.A. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 2009, 1:515-528.
126. Lamming D.W., Wood J.G., Sinclair D.A. Small molecules that regulate lifespan: evidence for xenohormesis. Mol. Microbiol. 2004, 53:1003-1009.
127. Howitz K.T., Sinclair D.A. Xenohormesis: sensing the chemical cues of other species. Cell 2008, 133:387-391.
128. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36:79-87.
129. Gresele P., Pignatelli P., Guglielmini G., Carnevale R., Mezzasoma A.M., Ghiselli A., Momi S., Violi F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J. Nutr. 2008, 138:1602-1608.
130. Chow H.H., Garland L.L., Hsu C.H., Vining D.R., Chew W.M., Miller J.A., Perloff M., Crowell J.A., Alberts D.S. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila.) 2010, 3:1168-1175.
131. Marier J.F., Vachon P., Gritsas A., Zhang J., Moreau J.P., Ducharme M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302:369-373.
132. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., Booth T.D., Crowell J.A., Perloff M., Gescher A.J., Steward W.P., Brenner D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1246-1252.
133. Patel K.R., Andreadi C., Britton R.G., Horner-Glister E., Karmokar A., Sale S., Brown V.A., Brenner D.E., Singh R., Steward W.P. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5. (205ra133-205ra133).
134. Bode L.M., Bunzel D., Huch M., Cho G.-S., Ruhland D., Bunzel M., Bub A., Franz C.M., Kulling S.E. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 2013, 97:295-309.
135. Vaz-da-Silva M., Loureiro A., Falcao A., Nunes T., Rocha J., Fernandes-Lopes C., Soares E., Wright L., Almeida L., Soares-da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int. J. Clin. Pharmacol. Ther. 2008, 46:564-570.
136. Almeida L., Vaz-da-Silva M., Falcão A., Soares E., Costa R., Loureiro A.I., Fernandes-Lopes C., Rocha J.F., Nunes T., Wright L. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53:S7-S15.
137. la Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., Cameron D.W. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 2010, 49:449-454.
138. Patel K.R., Brown V.A., Jones D.J., Britton R.G., Hemingway D., Miller A.S., West K.P., Booth T.D., Perloff M., Crowell J.A., Brenner D.E., Steward W.P., Gescher A.J., Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70:7392-7399.
139. Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., Levine B.S. Resveratrol-associated renal toxicity. Toxicol. Sci. 2004, 82:614-619.
140. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224:274-283.
141. Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., Brown K., Steward W.P., Gescher A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila.) 2011, 4:1419-1425.
142. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141:3657-3667.
143. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001, 15:1798-1800.
144. Leone S., Basso E., Polticelli F., Cozzi R. Resveratrol acts as a topoisomerase II poison in human glioma cells. Int. J. Cancer 2012, 131:E173-E178.
145. Paolini M., Sapone A., Valgimigli L. Avoidance of bioflavonoid supplements during pregnancy: a pathway to infant leukemia?. Mutat. Res. 2003, 527:99-101.
146. Elliott P.J., Jirousek M. Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs 2008, 9:371-378.
147. Yang H., Baur J.A., Chen A., Miller C., Sinclair D.A. Design and Synthesis of Compounds That Extend Yeast Replicative Lifespan. Aging Cell 2007, 6:35-43.
148. Nayagam V.M., Wang X., Tan Y.C., Poulsen A., Goh K.C., Ng T., Wang H., Song H.Y., Ni B., Entzeroth M., Stunkel W. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 2006, 11:959-967.
149. Gano L.B., Donato A.J., Pasha H.M., Hearon C.M., Sindler A.L., Seals D.R. The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production and inflammation with aging in mice. Am. J. Physiol. Heart Circ. Physiol. 2014, 307(12):H1754-H1763. (ajpheart 00377 02014). 10.1152/ajpheart.00377.
150. Gueguen C., Palmier B., Plotkine M., Marchand-Leroux C., Bessson V.C. Neurological and histological consequences induced by in vivo cerebral oxidative stress: evidence for beneficial effects of SRT1720, a sirtuin 1 activator, and sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition. PLoS One 2014, 9:e87367.
151. Minor R.K., Baur J.A., Gomes A.P., Ward T.M., Csiszar A., Mercken E.M., Abdelmohsen K., Shin Y.-K., Canto C., Scheibye-Knudsen M. SRT1720 improves survival and healthspan of obese mice. Sci. Rep. 2011, 1.
152. Mitchell S.J., Martin-Montalvo A., Mercken E.M., Palacios H.H., Ward T.M., Abulwerdi G., Minor R.K., Vlasuk G.P., Ellis J.L., Sinclair D.A. The SIRT1 Activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 2014, 6:836-843.
153. Mercken E.M., Mitchell S.J., Martin-Montalvo A., Minor R.K., Almeida M., Gomes A.P., Scheibye-Knudsen M., Palacios H.H., Licata J.J., Zhang Y. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 2014, 13:787-796.
154. Libri V., Brown A.P., Gambarota G., Haddad J., Shields G.S., Dawes H., Pinato D.J., Hoffman E., Elliot P.J., Vlasuk G.P., Jacobson E., Wilkins M.R., Matthews P.M. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One 2012, 7:e51395.
155. Hoffmann E., Wald J., Lavu S., Roberts J., Beaumont C., Haddad J., Elliott P., Westphal C., Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 2013, 75:186-196.
156. Viswanathan M., Kim S.K., Berdichevsky A., Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 2005, 9:605-615.
157. Bauer J.H., Goupil S., Garber G.B., Helfand S.L. An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12980-12985.
158. Carter L.G., D'Orazio J.A., Pearson K.J. Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 2014, 21(3):R209-R225. 10.1530/ERC-13-0171.
159. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011, 1215:9-15. 10.1111/j.1749-6632.2010.05842.x.